IBD: A growing and vulnerable cohort of hospitalized patients with clostridium difficile infection

American Surgeon

Volumn 83, Issue 6, 2017, Pages 605-609

  Mabardy, Allan ^a   McCarty, Justin ^a   Hackford, Alan ^a   Dao, Haisar ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; CONFERENCE PAPER; CONTROLLED STUDY; CROHN DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MORTALITY; PEPTOCLOSTRIDIUM DIFFICILE; POPULATION RESEARCH; UNITED STATES; CLOSTRIDIUM INFECTIONS; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; INFLAMMATORY BOWEL DISEASES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CLOSTRIDIUM INFECTIONS; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INPATIENTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85021102804     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703.
2. See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58:1394-400.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
4. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529-49.
5. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012;55:1661-8.
6. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365:1713-25.
7. Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010;16: 4892-904.
8. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51.
9. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-64.
10. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. Available at: http://www. hcup-us.ahrq.gov/home.jsp. Accessed March, 2016.
11. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50.
12. Ricciardi R, Ogilvie JW Jr, Roberts PL, et al. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009;52:40-5.
13. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:976-83.
14. Dubberke ER, Reske KA, McDonald LC, et al. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006;12:1576-9.
15. Meyer AM, Ramzan NN, Loftus EV Jr, et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772-5.